TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells

Epigenetics

Volumn 9, Issue 11, 2014, Pages 1461-1472

  Cardenas, Horacio ^a   Vieth, Edyta ^a   Lee, Jiyoon ^a   Segar, Mathew ^a   Liu, Yunlong ^a,b   Nephew, Kenneth P ^a,b,c,d   Matei, Daniela ^a,b,e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VA Roudebush Hospital   (United States)

Author keywords

DNA methylation; EMT; Ovarian cancer; SGI 110; TGF

Indexed keywords

COLLAGEN; COLLAGEN 1A1; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; NUCLEAR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; AZACITIDINE; CADHERIN; CDH1 PROTEIN, HUMAN; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; ENZYME INHIBITOR; SGI-110;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE; CELL DEATH; CELL MATURATION; CELL MOTION; CELL SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METASTASIS; MORPHOLOGY; OVARY CANCER; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE;

AZACITIDINE; CADHERINS; CELL LINE, TUMOR; COLLAGEN TYPE I; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84922024758     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/15592294.2014.971608     Document Type: Article

References (51)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:41528; PMID:12042769; http://dx.doi.org/10.1038/nrg962
2. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22:463242; PMID:15542813; http://dx.doi.org/10.1200/JCO.2004.07.151
3. Patra SK, Patra A, Rizzi F, Ghosh TC, Bettuzzi S. Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer Metast Rev 2008; 27:31534; PMID:18246412; http://dx.doi.org/ 10.1007/s10555-008-9118-y
4. Zhu JK. Active DNA demethylation mediated by DNA glycosylases. Annu Rev Genet 2009; 43:14366; PMID:19659441; http://dx.doi.org/10.1146/annurevgenet- 102108-134205
5. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466:112933; PMID:20639862; http://dx. doi.org/10.1038/nature09303
6. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:44254; PMID:12189386; http://dx.doi.org/10.1038/nrc822
7. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392:1903; PMID:9515965; http://dx.doi.org/10.1038/32433
8. Nagafuchi A, Shirayoshi Y, Okazaki K, Yasuda K, Takeichi M. Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature 1987; 329:3413; PMID:3498123; http://dx.doi.org/ 10.1038/329341a0
9. Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolós V, Jordá M, Fabra A, Portillo F, et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 2006; 66:954356; PMID:17018611; http://dx.doi.org/10.1158/0008- 5472.CAN-06-0479
10. Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, Oosting J, van Eijk R, Eilers PH, van de Water B, Cornelisse CJ, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 2006; 94:66171; PMID:16495925
11. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A 2008; 105:1486772; PMID:18806226; http://dx.doi.org/10.1073/ pnas.0807146105
12. Lin T, Ponn A, Hu X, Law BK, Lu J. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene 2010; 29:4896904; PMID:20562920; http://dx.doi.org/10.1038/ onc.2010.234
13. Dong C, Wu Y, Wang Y, Wang C, Kang T, Rychahou PG, Chi YI, Evers BM, Zhou BP. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene 2013; 32:135162; PMID:22562246; http://dx.doi.org/ 10.1038/onc.2012.169
14. Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou PG, Evers BM, Zhou BP. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest 2012; 122:146986; PMID:22406531; http://dx.doi.org/10.1172/JCI57349
15. Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor betaSmad signaling. Cancer Res 2003; 63:14139; PMID:12649207
16. Dowdy SC, Mariani A, Janknecht R. HER2Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol Chem 2003; 278:4437784; PMID: 12947087; http://dx.doi.org/10.1074/jbc.M307202200
17. Cardillo MR, Yap E, Castagna G. Molecular genetic analysis of TGF-beta1 in ovarian neoplasia. J Exp Clin Cancer Res 1997; 16:4956; PMID:9148861
18. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC, Jr., StackMS. Regulation of invasion of epithelial ovarian cancer by transforming growth factorbeta. Gynecol Oncol 2001; 80:24553; PMID:11161867; http://dx.doi.org/10.1006/gyno.2000.6042
19. Wakahara K, Kobayashi H, Yagyu T, Matsuzaki H, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, et al. Transforming growth factor-beta1- dependent activation of Smad23 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells. J Cell Biochem 2004; 93:43753; PMID:15372629; http://dx.doi.org/ 10.1002/jcb.20160
20. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 2012; 31:252134; PMID:21963846; http://dx.doi.org/10.1038/onc. 2011.429
21. Abendstein B, Stadlmann S, Knabbe C, Buck M, Muller-Holzner E, Zeimet AG, Marth C, Obrist P, Krugmann J, Offner FA. Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells. Cytokine 2000; 12:11159; PMID:10880260; http://dx.doi.org/ 10.1006/cyto.1999.0632
22. Bartlett JM, Langdon SP, Scott WN, Love SB, Miller EP, Katsaros D, Smyth JF, Miller WR. Transforming growth factor-beta isoform expression in human ovarian tumours. Eur J Cancer 1997; 33:2397403; PMID:9616289; http://dx.doi.org/10.1016/S0959- 8049(97)00304-3
23. Bristow RE, Baldwin RL, Yamada SD, Korc M, Karlan BY. Altered expression of transforming growth factorbeta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer 1999; 85:65868; PMID:10091739; http://dx.doi.org/10.1002/(SICI) 1097-0142(19990201)85:3%3c658::AID-CNCR16% 3e3.0.CO;2-M
24. Massague J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell 1996; 85:94750; PMID: 8674122; http://dx.doi.org/10.1016/S0092-8674(00) 81296-9
25. Chen T, Triplett J, Dehner B, Hurst B, Colligan B, Pemberton J, Graff JR, Carter JH. Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 2001; 61:467982; PMID:11406536
26. Lynch MA, Nakashima R, Song H, DeGroff VL, Wang D, Enomoto T, Weghorst CM. Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res 1998; 58:422732; PMID:9766642
27. Yang AS, EstecioMR,Doshi K, Kondo Y,Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32:e38; PMID:14973332; http://dx.doi.org/10.1093/nar/gnh032
28. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005; 33:682336; PMID: 16326863; http://dx.doi.org/10.1093/nar/gki987
29. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, et al. DNA methylation changes after 5-aza-2'- deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66:5495503; PMID:16707479; http:// dx.doi.org/10.1158/0008-5472.CAN-05-2385
30. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324:9305; PMID:19372391; http://dx.doi.org/10.1126/science.1170116
31. Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U, Alekseyev YO, Thiagalingam A, Abdolmaleky HM, Lenburg M, et al. Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res 2010; 70:96878; PMID:20086175; http://dx.doi.org/10.1158/0008- 5472.CAN-09-1872
32. Foulks JM, Parnell KM, Nix RN, Chau S, Swierczek K, Saunders M, Wright K, Hendrickson TF, Ho KK, McCullar MV, et al. Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen 2012; 17:217; PMID:21965114; http://dx.doi.org/10.1177/ 1087057111421212
33. Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD, Oganesian A, Taverna P, Belinsky SA. SGI- 110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int J Cancer J 2014; PMID:24668305
34. Beauchef G, Bigot N, Kypriotou M, Renard E, Poree B, Widom R, Dompmartin-Blanchere A, Oddos T, Maquart FX, Demoor Mk, et al. The p65 subunit of NF-kappaB inhibits COL1A1 gene transcription in human dermal and scleroderma fibroblasts through its recruitment on promoter by protein interaction with transcriptional activators (c-Krox, Sp1, and Sp3). J Biol Chem 2012; 287:346278; PMID:22139845; http://dx. doi.org/10.1074/jbc.M111.286443
35. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:14208; PMID:19487818; http://dx.doi.org/10.1172/JCI39104
36. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:70415; PMID:18485877; http://dx.doi.org/ 10.1016/j.cell.2008.03.027
37. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27:727484; PMID:18806826; http://dx.doi.org/10.1038/onc. 2008.333
38. Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, Escrivá M, Hernandez-Muñoz I, Di Croce L, Helin K, et al. Polycomb complex 2 is required for Ecadherin repression by the Snail1 transcription factor. Mol Cell Biol 2008; 28:477281; PMID:18519590; http://dx.doi.org/10.1128/MCB.00323-08
39. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D'Alessio AC, Young RA, Weinberg RA. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154:6174; PMID:23827675; http://dx.doi.org/ 10.1016/j.cell.2013.06.005
40. O'Hagan HM, Mohammad HP, Baylin SB. Double strand breaks can initiate gene silencing and SIRT1- dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet 2008; 4:e1000155; http://dx.doi.org/10.1371/journal.pgen.1000155
41. O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, Clements EG, Cai Y, Van Neste L, Easwaran H, et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 2011; 20:60619; PMID:22094255; http://dx.doi.org/ 10.1016/j.ccr.2011.09.012
42. Roll JD, Rivenbark AG, Sandhu R, Parker JS, Jones WD, Carey LA, Livasy CA, Coleman WB. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Exp Mol Pathol 2013; 95:27687; PMID:24045095; http://dx.doi.org/ 10.1016/j.yexmp.2013.09.001
43. Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, Feng J, Yang D, Fu L, Yan X. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci U S A 2012; 109:112732; PMID:22210108; http://dx.doi.org/ 10.1073/pnas.1111053108
44. Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, Jelinek J, Yamazaki J, Raynal NJ, Long H. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biol 2013; 14:R144; PMID:24367927; http://dx.doi.org/10.1186/gb-2013-14-12-r144
45. Fang F, Zuo Q, Pilrose J, Wang Y, Shen C, Li M, Wulfridge P, Matei D, Nephew KP. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget 2014; 5:357989; PMID:25003579
46. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012; 72:2197205; PMID:22549947; http://dx. doi.org/10.1158/0008-5472.CAN-11-3909
47. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012; 21:43046; PMID:22439938; http://dx.doi.org/10.1016/j.ccr.2011.12.029
48. Naeem H, Wong NC, Chatterton Z, Hong MK, Pedersen JS, Corcoran NM, Hovens CM, Macintyre G. Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics 2014; 15:51; PMID:24447442; http://dx.doi.org/10.1186/1471-2164-15-51
49. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22:25588; PMID:11294827
50. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010; 11:587; PMID:21118553; http://dx.doi.org/10.1186/1471- 2105-11-587
51. Benjamini Y, Yekutieli, D. The control of the false discovery rate in multiple testing under dependency Ann Stat 2001; 29:116588; http://dx.doi.org/10.1214/aos/ 1013699998